title: Therapeutic strategies in gastric cancer.
abstract: Gastric cancer continues to be a major public health problem and is the second most common cause of cancer-related deaths in the world. These statistics led the American Society of Clinical Oncology (ASCO) International Affairs Committee to choose gastric cancer as the topic for the International Symposium held at the 2003 ASCO Annual Meeting. Dr Yoshiaki Ito will discuss the role of RUNX3 in the genesis and progression of human gastric cancer. Dr Pelayo Correa will present a compelling argument on the use of Helicobacter pylori therapy and antioxidants in selected high-risk population as chemoprevention strategies for gastric cancer. The controversy regarding the role of extended lymph node dissection for gastric cancer will be discussed by Dr Cornelis J.H. Van De Velde and Dr Mitsuru Sasako. Dr Van De Velde will present the European surgical approach to gastric cancer, and Dr Sasako will review the Japanese experience. The issues of whether certain patients benefit from more aggressive surgical dissection and the potential risks compared with benefits will also be discussed. Dr John Macdonald will discuss the role of adjuvant chemotherapy and adjuvant chemoradiotherapy in resected gastric cancer, as well as the role of chemotherapy in metastatic gastric cancer.
authors.affiliation: Faculty of Medicine, National University of Singapore, and the Institute of Molecualr and Cell Biology, Sigapore. johnwong@nus.edu.sg
authors.forename: J E L
authors.initials: JE
authors.lastname: Wong
authors.forename: Y
authors.initials: Y
authors.lastname: Ito
authors.forename: P
authors.initials: P
authors.lastname: Correa
authors.forename: K C M J
authors.initials: KC
authors.lastname: Peeters
authors.forename: C J H
authors.initials: CJ
authors.lastname: van de Velde
authors.forename: M
authors.initials: M
authors.lastname: Sasako
authors.forename: J
authors.initials: J
authors.lastname: Macdonald
mesh_terms: D000818:Animals; D001374:Azacitidine / Q000494:pharmacology; D050677:Core Binding Factor Alpha 3 Subunit; D004268:DNA-Binding Proteins / Q000502:physiology*; D004791:Enzyme Inhibitors; D020868:Gene Silencing / Q000187:drug effects; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D008780:Methyltransferases / Q000037:antagonists & inhibitors; D051379:Mice; D008819:Mice, Nude; D013274:Stomach Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D014157:Transcription Factors / Q000502:physiology*; D014407:Tumor Cells, Cultured; D025521:Tumor Suppressor Proteins / Q000502:physiology*
chemical_list: D050677:Core Binding Factor Alpha 3 Subunit; D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; C493729:Runx3 protein, human; C493730:Runx3 protein, mouse; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C012589:trichostatin A; D008780:Methyltransferases; D001374:Azacitidine